SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-018794
Filing Date
2023-05-08
Accepted
2023-05-08 16:07:04
Documents
14
Period of Report
2023-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sndx-20230505.htm   iXBRL 8-K 60643
2 EX-99.1 sndx-ex99_1.htm EX-99 188869
3 GRAPHIC img199102934_0.jpg GRAPHIC 14374
  Complete submission text file 0000950170-23-018794.txt   402310

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sndx-20230505.xsd EX-101.SCH 2463
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sndx-20230505_lab.xml EX-101.LAB 13916
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sndx-20230505_pre.xml EX-101.PRE 10229
8 EXTRACTED XBRL INSTANCE DOCUMENT sndx-20230505_htm.xml XML 4869
Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

IRS No.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37708 | Film No.: 23897753
SIC: 2834 Pharmaceutical Preparations